Article Sidebar
Published:
Nov 6, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Preliminary study on the relationship between recurrence and quasispecies characteristics in P region of hepatitis B virus genome of chronic hepatitis B patients treated with lamivudine
Abstract
Purpose: To investigate the characteristics of quasispecies in the P region of hepatitis B viral (HBV) DNA of chronic hepatitis B (CHB) patients treated with lamivudine (LAM), and its effect on HBV relapse after drug withdrawal in CHB patients who met drug cessation criteria.
Methods: A total of 43 patients with chronic HBV infection, who had undergone LAM therapy, were enrolled in this study. Treatment was discontinued for patients who met therapeutic criteria set by relevant Asian-Pacific regions. Polymerase chain reaction (PCR) was used to amplify the genome in P region of serum rcDNA before treatment, cccDNA during drug cessation period, and serum rcDNA at relapse. Quasispecies cloning and sequencing were performed to identify variable sites in HBV P region.
Results: Mutations in P region of baseline serum rcDNA were detected in 30 CHB patients, with N/H238T (14/30), L/F/Q/R267H (12/30), V278T (12/30), D134E/I (11/30), and T222A (9/30) having highest rates. In hepatocellular cccDNA P region during drug withdrawal, most detectable mutations were L/F/Q/R267H (25/43), V278T (18/43), N/H238T (15/43), D134E/I (14/43), and T222A (11/43). During relapse, the highest detectable mutation rates in serum rcDNA P region were N/H238T (12/19), L/F/Q/R267H (10/19), T222A (10/19), and V278T (8/19).
Conclusion: High mutation rates of T222A and N/H238T in P region of HBV DNA increase the risk of relapse in patients. As a result, patients are susceptible to relapse after drug withdrawal.
